The role of AIB1 in breast cancer (review)

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 588-594

  Chang, Alan K ^a   Huijian, W U ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

AIB1; Breast cancer; Hormone dependent signaling; Nuclear receptors

Indexed keywords

ESTROGEN RECEPTOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P53; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR E2F1; UBIQUITIN PROTEIN LIGASE;

ACETYLATION; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; DEACETYLATION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; METHYLATION; NONHUMAN; PANCREAS CANCER; PLEIOTROPY; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; STOMACH CANCER; SUMOYLATION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

EID: 84864695853     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.803     Document Type: Review

References (77)

1. Xu J and Li Q: Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17: 1681-1692, 2003.
2. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968, 1997.
3. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR and Brown M: High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6: 263-274, 2004.
4. Kuang SQ, Liao L, Zhang H, Lee AV, O'Malley BW and Xu J: AIB1/SRC-3 deficiency affects insulin-like growth factor 1 signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 64: 1875-1885, 2004.
5. Kuang SQ, Liao L, Wang S, Medina D, O'Malley BW and Xu J: Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res 65: 7993-8002, 2005.
6. Coste A, Antal MC, Chan S, Kastner P, Mark M, O'Malley BW and Auwerx J: Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J 25: 2453-2464, 2006.
7. Ma G, Ren Y, Wang K and He J: SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci 7: 664-672, 2011.
8. Werbajh S, Nojek I, Lanz R and Costas MA: RAC-3 is a NF-kappa B coactivator. FEBS Lett 485: 195-199, 2000.
9. Louie MC, Zou JX, Rabinovich A and Chen HW: ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 24: 5157-5171, 2004.
10. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y and Iwase H: Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100: 2028-2033, 2009.
11. Liao L, Kuang SQ, Yuan Y, Gonzalez SM, O'Malley BW and Xu J: Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J Steroid Biochem Mol Bio 83: 3-14, 2002.
12. Yan J, Tsai SY and Tsai MJ: SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 27: 387-394, 2006.
13. Amazit L, Pasini L, Szafran AT, Berno V, Wu RC, Mielke M, Jones ED, Mancini MG, Hinojos CA, O'Malley BW and Mancini MA: Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol Cell Biol 27: 6913-6932, 2007.
14. Lahusen T, Henke RT, Kagan BL, Wellstein A and Riegel AT: The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 116: 225-237, 2009.
15. Xu J, Wu RC and O'Malley BW: Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9: 615-630, 2009.
16. Gojis O, Rudraraju B, Alifrangis C, Krell J, Libalova P and Palmieri C: The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol 36: 224-229, 2010.
17. Gojis O, Rudraraju B, Gudi M, Hogben K, Sousha S, Coombes RC, Cleator S and Palmieri C: The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol 7: 83-89, 2010.
18. Lydon JP and O'Malley BW: Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology 152: 19-25, 2011.
19. Johnson AB and O'Malley BW: Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cel Endocrinol 348: 430-439, 2012.
20. Savkur RS and Burris TP: The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 63: 207-212, 2004.
21. Chen H, Lin RJ, Schilz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y and Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with p/CAF and CBP/300. Cell 90: 569-580, 1997.
22. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P and Gronemeyer H: The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 17: 507-519, 1998.
23. Li J, O'Malley BW and Wong J: p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. Mol Cell Biol 20: 2031-2042, 2000.
24. Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM and Zhu YJ: Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha. J Biol Chem 277: 28624-28630, 2002.
25. Teyssier C, Chen D and Stallcup MR: Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function. J Biol Chem 277: 46066-46072, 2002.
26. Lee DY, Teyssier C, Strahl BD and Stallcup MR: Role of protein methylation in regulation of transcription. Endocr Rev 26: 147-170, 2005.
27. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ and O'Malley BW: Steroid receptor coactivator-1 is a histone acetyl transferase. Nature 389: 194-198, 1997.
28. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW and Stallcup MR: Regulation of transcription by a protein methyltransferase. Science 284: 2174-2177, 1999.
29. Koh SS, Chen D, Lee YH and Stallcup MR: Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem 276: 1089-1098, 2001.
30. Wu RC, Smith CL and O'Malley BW: Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev 26: 393-399, 2005.
31. Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, Dakshanamurthy S, Xu J, Kagan BL, Wellstein A and Riegel AT: Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol Cell Biol 28: 6580-6593, 2008.
32. Li C, Liang YY, Feng XH, Tsai SY, Tsai MJ and O'Malley BW: Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol Cell 31: 835-849, 2008.
33. Yi P, Feng Q, Amazit L, Lonard DM, Tsai SY, Tsai MJ and O'Malley BW: Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell 29: 465-476, 2008.
34. Li C, Ao J, Fu J, Lee DF, Xu J, Lonard D and O'Malley BW: Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 30: 4350-4364, 2011.
35. Wu H, Sun L, Zhang Y, Chen Y, Shi B, Li R, Wang Y, Liang J, Fan D, Wu G, et al: Coordinated regulation of AIB1 transcriptional activity by sumolylation and phosphorylation. J Biol Chem 281: 21848-21856, 2006.
36. Li S, Yang C, Hong Y, Bi H, Zhao F, Liu Y, Ao X, Pang P, Xing X, Chang AK, et al: The transcriptional activity of co-activator AIB1 is regulated by the SUMO E3 Ligase PIAS1. Biol Cell 104: 287-296, 2012.
37. Labhart P, Karmakar S, Salicru EM, Egan BS, Alexiadis V, O'Malley BW and Smith CL: Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci USA 102: 1339-1344, 2005.
38. Li S and Shang Y: Regulation of SRC family coactivators by post-translational modifications. Cell Signal 19: 1101-1112, 2007.
39. Bautista S, Vallès H, Walker RL, Anzick S, Zeillinger R, Meltzer P and Theillet C: In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4: 2925-2929, 1998.
40. Glaeser M, Floetotto T, Hanstein B, Beckmann MW and Niederacher D: Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res 33: 121-126, 2001.
41. List HJ, Reiter R, Singh B, Wellstein A and Riegel AT: Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 68: 21-28, 2001.
42. Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T and Inazawa J: Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 98: 18-23, 2003.
43. Qin L, Liao L, Redmond A, Young L, Yuan Y, Chen H, O'Malley BW and Xu J: The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metallopteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 28: 5937-5950, 2008.
44. Kirkegaard T, McGlynn LM, Campbell FM, Müller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG and Bartlett JM: Amplified in breast cancer 1 in human epidermal growth factor receptor- positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13: 1405-1411, 2007.
45. Bouras T, Southey MC and Venter DJ: Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 61: 903-907, 2001.
46. Lee K, Lee A, Song BJ and Kang CS: Expression of AIB1 protein as a prognostic factor in breast cancer. World J Sur Oncol 9: 139, 2011.
47. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE and Robson CN: Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85: 1928-1936, 2001.
48. Barkhem T, Nilsson S and Gustafsson JA: Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics 4: 19-28, 2004.
49. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A and Riegel AT: Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276: 23763-23768, 2001.
50. Karmakar S, Foster EA and Smith CL: Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology 150: 1588-1596, 2009.
51. Karmakar S, Gao T, Pace MC, Oesterreich S and Smith CL: Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor. Mol Endocrinol 24: 1187-1202, 2010.
52. Fereshteh MP, Tilli MT, Kim SE, Xu J, O'Malley BW, Wellstein A, Furth PA and Riegel AT: The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 68: 3697-3706, 2008.
53. Alkner S, Bendahl PO, Grabau D, Lövgren K, Stål O, Rydén L and Fernö M; Swedish and South-East Swedish Breast Cancer Groups: AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 21: 238-244, 2010.
54. Su Q, Hu S, Gao H, Ma R, Yang Q, Pan Z, Wang T and Li F: Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology 75: 159-168, 2008.
55. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M and Schiff R: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: 826-833, 2008.
56. Karmakar S, Foster EA, Blackmore JK and Smith CL: Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line. Endocr Relat Cancer 18: 113-127, 2011.
57. Osborne CK, Shou J, Massarweh S and Schiff R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865s-870s, 2005.
58. Arpino G, Wiechmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233, 2008.
59. Reiter R, Oh AS, Wellstein A and Riegel AT: Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene 23: 403-409, 2004.
60. Lanz RB, Bulynko Y, Malovannaya A, Labhart P, Wang L, Li W, Qin J, Harper M and O'Malley BW: Global characterization of transcriptional impact of the SRC-3 coregulator. Mol Endocrinol 24: 859-872, 2010.
61. Torres-Arzayus MI, Zhao J, Bronson R and Brown M: Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. Cancer Res 70: 4102-4111, 2010.
62. Silva CM and Shupnik MA: Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol Endocrinol 21: 1499-1512, 2007.
63. Oh A, List HJ, Reiter R, Mani A, Zhang Y, Gehan E, Wellstein A and Riegel AT: The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 64: 8299-8308, 2004.
64. Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY and Tsai MJ: Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 66: 11039-11046, 2006.
65. Liao L, Chen X, Wang S, Parlow AF and Xu J: Steroid receptor coactivator 3 maintains circulating insulin-like growth factor (IGF-I) by controlling IGF-binding protein 3 expression. Mol Cell Biol 28: 2460-2469, 2008.
66. Torres-Arzayus MI, Yuan J, DellaGatta JL, Lane H, Kung AL and Brown M: Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Cancer Res 66: 11381-11388, 2006.
67. Hardy KM, Booth BW, Hendrix MJ, Salomon DS and Strizzi L: ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 15: 191-199, 2010.
68. Lahusen T, Fereshteh M, Oh A, Wellstein A and Riegel AT: Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res 67: 7256-7265, 2007.
69. Long W, Yi P, Amazit L, LaMarca HL, Ashcroft F, Kumar R, Mancini MA, Tsai SY, Tsai MJ and O'Malley BW: SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell 37: 321-332, 2010.
70. Colo GP, Rosato RR, Grant S and Costas MA: RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett 581: 5075-5081, 2007.
71. Colo GP, Rubio MF, Nojek IM, Werbajh SE, Echeverría PC, Alvarado CV, Nahmod VE, Galigniana MD and Costas MA: The p160 nuclear receptor co-activator RAC3 exerts an anti-apoptotic role through a cytoplasmatic action. Oncogene 27: 2430-2444, 2008.
72. Ferragud J, Avivar-Valderas A, Pla A, De Las Rivas J and de Mora JF: Transcriptional repression of the tumor suppressor DRO1 by AIB1. FEBS Lett 585: 3041-3046, 2011.
73. Aoki K, Sun YJ, Aoki S, Wada K and Wada E: Cloning, expression, and mapping of a gene that is upregulated in adipose tissue of mice deficient in bombesin receptor subtype-3. Biochem Biophys Res Commun 290: 1282-1288, 2002.
74. Bommer GT, Jäger C, Dürr EM, Baehs S, Eichhorst ST, Brabletz T, Hu G, Fröhlich T, Arnold G, Kress DC, et al: DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells. J Biol Chem 280: 7962-7975, 2005.
75. Tremblay F, Revett T, Huard C, Zhang Y, Tobin JF, Martinez RV and Gimeno RE: Bidirectional modulation of adipogenesis by the secreted protein Ccdc80/DRO1/URB. J Biol Chem 284: 8136-8147, 2009.
76. Corkery D, Thillainadesan G, Coughlan N, Mohan RD, Isovic M, Tini M and Torchia J: Regulation of the BRCA1 gene by an SRC3/53BP1 complex. BMC Biochem 12: 50, 2011.
77. Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247, 2011.